Video Workshop Cervical cancer screening as a multidisciplinary process

Similar documents
EU guidelines for reporting gynaecological cytology

How invasive cervical cancer audit affects clinical practice

Management of Abnormal Cervical Cytology and Histology

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)

Colposcopy. Attila L Major, MD, PhD

Understanding Your Pap Test Results

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Chapter 10: Pap Test Results

Scottish Cervical Screening Programme. Colposcopy and Programme Management

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

Cervical Cancer : Pap smear

Cervical Conization. 1

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

BC Cancer Cervix Screening 2015 Program Results. February 2018

HKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists

EFCS Symposium. Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived?

Cytology Report Format

Making Sense of Cervical Cancer Screening

WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1

I have no financial interests in any product I will discuss today.

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Becoming a colposcopist: Colposcope case studies

Clinical Practice Guidelines June 2013

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

Associate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran.

Cervical Cancer Screening. David Quinlan December 2013

CPC on Cervical Pathology

I have no financial interests in any product I will discuss today.

Beatrix Cochand-Priollet. An overview of terminologies in cervical cytology in Europe

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

Table of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS

The society for lower genital tract disorders since 1964.

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

Cervical Dysplasia and HPV

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

I have no financial interests in any product I will discuss today.

International Journal of Health Sciences and Research ISSN:

GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) Approved by Guidelines Assessment Panel

LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation

Histopathology: Cervical HPV and neoplasia

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

Managament of Abnormal Cervical Cytology and Histology

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

CERVICAL CANCER FACTSHEET. What is cervical cancer?

Vagina. 1. Introduction. 1.1 General Information and Aetiology

Investigation of 100 consecutive negative cone biopsies

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

I have no financial interests to disclose.

Proposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Can LBC Completely Replace Conventional Pap Smear in Developing Countries

Eradicating Mortality from Cervical Cancer

Guidelines for Breast, Cervical and Colorectal Cancer Screening

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

King s Research Portal

RESULTS OF BREAST AND CERVICAL CANCERS SCREENING IN HAIPHONG WITHIN 5 YEARS FROM 2011 TO Hoa Nguyen Lam, Huyen Suong Ho Thi et al.

Chapter 8 Adenocarcinoma

National Cervical Screening Program MBS Item Descriptors

Cervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital

Portinari: A Data Exploration Tool to Personalize Cervical Cancer Screening

Cytology Update M Laing QEUH

Study of Cervical Pap Smears in a Tertiary Hospital

Pap Smear and Histopathological Study of Cervical Lesions

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Proposed New Guidelines for the Management of Women with Abnormal Cervical Smears DRAFT FOR COMMENT

WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS

Colposcopic Principles. Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK

Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow

6 th EFC Satellite meeting, Saturday 1 st December 2018

EFC and European Standards for Colposcopic Evaluation

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital

Details of HPV-based Cervical Cancer Screening in Turkey

Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.

The Role of The Advanced Practitioner in Cytology

A Study on Diagnostic Accuracy of Cervical Pap Smear by Correlating with Histopathology in a Tertiary Care Centre

Histopathological Correlation with Cervical Cytology

L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin

Risk of invasive cancer after colposcopy with and without biopsy

Conflict of Interest Disclosure. Anita L. Nelson, MD. Principles Underlying Screening Recommendations. Learning Objectives

Twenty-first refresher course. Chan Kit Sheung

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

Management that provides continuity of care for women

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

The routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy

TISSUE TUMOR MARKER EXPRESSION IN

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

Transcription:

Video Workshop Cervical cancer screening as a multidisciplinary process Dr. Amanda Herbert (Guy s & St Thomas NHS Foundation Trust, London) Professor Jaroslava Duskova (Charles University, Prague, Czech Republic)

Importance of MDT meetings Cervical cancer screening is a multidisciplinary process involving invitations to and clinical interaction with patients, cytology screening and reporting, HPV testing, colposcopy, histopathology and follow up MDT discussion allows mutual understanding of each others problems and when done before treatment may prevent mistakes happening in the first place Invasive cancer audit allows all aspect of the screening process to be reviewed to identify i) reasons why cancer was not detected or prevented and ii) areas where procedures could be improved

A multidisciplinary approach to cervical screening is the basis for the new gynaecological cytology chapters of the Eurocytology teaching programme http://www.eurocytology.eu/

Case 1. High grade lesion in a young patient (24) without reproduction plans fulfilled. 10 years lasting disease of the cervix. 26 cytologies 8 biopsies 3 conisations 3 HPV tests

April 2006: referred from a district hospital after HSIL and conisation. Exocervical margin was positive. Cytology and biopsy repeated on admission to the Faculty gynaecological oncology register. Cytology HSIL G 2937/06

April 2006: Punch biopsy CIN2-CIN3 B 7877/06

May 2006: second conisation. Exocervical margin was again positive! B 9471/06 CIN III

July 2006: cytology ASC-H (HSIL in revision repair features interfered in decision); biopsy or control cytology after 3 months recommended Cytology HSIL G 4589/06

September 2006: cytology and simultaneous biopsy. Cytology false negative, in revision HSIL ( just a few inaparent but diagnostic groups). Cytology HSIL G 5685/06

September 2006: cytology and simultaneous biopsy. Biopsy CIN III-CIS G 5685/06, B 16400/06

p16 October 2006: Biopsy - negative MIB1

January 2007: cytology HSIL and glandular atypia slide lost February 2007: cytology H SIL and inflammation three experts reading Cytology HSIL G 1314/07

April 2007: third conisation focal high grade confirmed. Margins negative. CIN II B 6862/07

September 2007: cytology benign cellular changes December 2007: cytology unsatisfactory - obscured with blood February 2008: cytology benign cellular changes Generally, poorly evaluable slides

September 2008: cytology ASC-H, AGC-NOS lost slide Simultaneous biopsy endocervical hyperplastic polyp

September 2008: cytology ASC-H, AGC-NOS lost slide Simultaneous biopsy endocervical hyperplastic polyp glandular structures

September 2008: cytology ASC-H, AGC-NOS (lost slide) Simultaneous biopsy endocervical hyperplastic polyp immature metaplasia

November 2008: biopsy questionable CIN1, koilocytes (?). Simultaneous cytology benign cellular changes. 1st HPV test 16, 18 - negative

June 2009: biopsy CIN1, koilocytes. Salpingeal metaplasia. B 11532/09

November 2009: cytology ASC-US, AGUS Generally, poorly evaluable slides G 2994/09

June 2010: cytology LSIL December 2010: cytology ASC-US 2nd HPV test 16,18 negative. Generally, poorly evaluable slides S 3713/10; S6584/13

June 2011: cytology AGC NOS December 2011 ASC-US: cytology S 3045/11 Generally, poorly evaluable slides

April 2012: cytology AGC-NOS October 2012: cytology NILM May 2013: cytology AGC-NOS 3rd HPV test 16,18 negative. Generally, poorly evaluable slides S 4819/12; S 2088/13

April 2014: cytology AGC-NOS November 2014: cytology NILM Generally, poorly evaluable slides ND 301/14; AB352/14

June 2015: cytology ASC-US November 2015: cytology NILM AB 318/15; AB 500/15 Readability of slides improves with time

Case 1 - Summary High grade lesion in a young patient (24) without reproduction plans fulfilled : 10 years lasting disease of the cervix. 26 cytologies positive- uncertain- normal 8 biopsies positive & negative -reactive 3 conisations positive - twice including positive margins 3 HPV tests ( of cure) all three negative The patient, now 34 years old, has (theoretically) her fertility preserved. Recently, she is on contraceptive drugs (Vreya).

Case presentation No. 4 (JD) Invasive carcinoma in a menopausal patient (55) discovered by the colposcopist three years after two negative cytologies. Born 1952. Referred 2007 by the local gynecologist to the university centre because of abnormal colposcopy finding. Cervix labium posterius ulceration 10 mm in diameter. Previous cytologies-twice-2004 NILM.

Previous cytologies: 2004 - twice - NILM G6726/04

Punch biopsy 2007 squamous carcinoma with clear cell component B3280/07

Therapy - 1/2 Surgery complete hysterectomy: squamous carcinoma with clear cell component; G3, pt1b1, N1 sentinel lymph node intraoperatively NEGATIVE subsequently semiseries according to the SLN protocol NEGATIVE etage lymphadenectomy 1 (other than SLN) out of 45 lymph nodes positive EFCS Tutorial

Hysterectomy 2007 squamous carcinoma with clear cell component; G3, pt1b1, N1; micrometastasis in one out of 45 lymph nodes investigated. B5883/07

Therapy 2/2 External radiotherapy 46Gy complications: perforation of the intestine peritonitis appendectomy CURED Cytology follow-up twice a year EFCS Tutorial

March 2008: cytology vaginal fornix - NILM September 2008: cytology vaginal fornix reactive changes G4405/08 S 2766/07

March 2009: cytology vaginal fornix ASC-US September 2009: cytology vaginal fornix - ASC-US reactive - jd G 2644/09 G975/09

March 2010: cytology vaginal fornix - NILM October 2010: cytology - vaginal fornix - NILM inflamm. repair - jd S 5079/10 S 1686/10

Recent status lymphoedemas treated vaginal findings stabilized dismissed to the local gynecologist care EFCS Tutorial

Case 4 - Summary Invasive carcinoma in a menopausal patient (55) discovered by the colposcopist three years after two negative cytologies Born 1952 Referred 2007 by the local gynecologist to the university centre because of abnormal colposcopy finding. Cervix labium posterius ulceration 10 mm in diameter. Previous cytologies-twice-2004 NILM. Squamous cell carcinoma diagnosed with punch biopsy Treated with surgery and external irradiation Older women frequently cease to visit gynecologist Any abnormal finding deserves to be clarified irrespective of the cytology result(s). Postoperative plus post-irradiation changes can make the evaluation of follow up cytologies difficult.

Video Workshop Cervical cancer screening as a multidisciplinary process Thank you for your attention!